Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$9.77
$0.49
$2.60
$2.35B1.5539,610 shs3.45 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$19.58
+4.3%
$19.79
$16.67
$22.00
$1.23B0.37824,792 shs1.26 million shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.87
$70.90
$131.98
$14.05B0.691.54 million shsN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$38.92
+5.0%
$36.05
$16.65
$46.48
$6.18B1.912.49 million shs1.63 million shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.36
$4.48
$3.55
$16.11
$197.42M0.51315,289 shs89,025 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%-2.24%-13.46%+4.39%+12.19%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%0.00%+68.78%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
0.00%-0.32%+2.97%-3.46%+74.99%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%+1.28%-7.43%-11.56%-65.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
4.0996 of 5 stars
3.50.00.04.22.11.71.9
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.672 of 5 stars
1.10.00.04.50.01.70.6
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
3.552 of 5 stars
2.40.00.03.52.32.51.9
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
4.1902 of 5 stars
4.45.00.00.03.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
0.00
N/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
3.00
Buy$40.33105.99% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.80
Moderate Buy$43.8012.54% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$15.60257.80% Upside

Current Analyst Ratings Breakdown

Latest ITCI, BLUSF, YMAB, INVA, and TGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Innoviva, Inc. stock logo
INVA
Innoviva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
7/11/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$26.00
7/10/2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$37.00
5/29/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.00
5/28/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00 ➝ $18.00
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
4/22/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
$30K0.00N/AN/A$0.25 per share0.00
Innoviva, Inc. stock logo
INVA
Innoviva
$358.71M3.43$3.57 per share5.48$11.03 per share1.78
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$329M18.78$0.13 per share309.14$1.43 per share27.22
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M2.25N/AN/A$2.05 per share2.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/A
Innoviva, Inc. stock logo
INVA
Innoviva
$23.39M-$1.01N/A12.63N/A-16.15%15.77%8.41%7/29/2025 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$23.38M$0.24162.1738.92N/A10.13%18.88%7.05%8/5/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)

Latest ITCI, BLUSF, YMAB, INVA, and TGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.27N/AN/AN/A$18.40 millionN/A
8/5/2025Q2 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.27N/AN/AN/A$147.76 millionN/A
7/29/2025Q2 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.43N/AN/AN/A$87.10 millionN/A
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
5/7/2025Q1 2025
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.25N/A-$0.74N/A$88.63 million
5/7/2025Q1 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.19$0.03-$0.16$0.03$117.07 million$120.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/A
13.87
13.87
Innoviva, Inc. stock logo
INVA
Innoviva
0.40
2.48
2.30
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.03
4.02
3.04
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.77
4.35

Institutional Ownership

CompanyInstitutional Ownership
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
N/A
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
24.17%
Innoviva, Inc. stock logo
INVA
Innoviva
2.25%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
10.64%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
BELLUS Health Inc stock logo
BLUSF
BELLUS Health
10159.12 millionN/ANot Optionable
Innoviva, Inc. stock logo
INVA
Innoviva
10062.78 million61.36 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.76 million141.86 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million36.36 millionOptionable

Recent News About These Companies

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha
Y mAbs Therapeutics News (YMAB) - Investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BELLUS Health stock logo

BELLUS Health OTCMKTS:BLUSF

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Innoviva stock logo

Innoviva NASDAQ:INVA

$19.58 +0.81 (+4.32%)
Closing price 04:00 PM Eastern
Extended Trading
$20.06 +0.48 (+2.43%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)
As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$38.92 +1.84 (+4.96%)
Closing price 04:00 PM Eastern
Extended Trading
$38.88 -0.04 (-0.10%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.36 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$4.36 0.00 (0.00%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.